Algernon Pharmaceuticals Inc (AGNPF)

[tcm55]

Interesting wording in the PR could have used better definitions. My thoughts in ("")...GLTA...
ie.

"The primary focus of the Phase 1 DMT study is to investigate prolonged intravenous infusion of DMT, ("6 hr microdose") for durations which have never been clinically studied. (" in humans!")... The resulting data generated will help the Company to plan both its Phase 2 ""acute stroke"!" and ""rehabilitation"!" studies more effectively.

“We look forward to getting our DMT clinical stroke program started with our Phase 1 study at Hammersmith Medicines Research in the UK,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “This study will provide """"important information on dosage and duration of our new DMT IV formula""!"" to help us better plan for our Phase 2 study where we plan to test the drug with both ""!""acute and recovering stroke patients""!"".”

Phase 1 DMT Stroke Study Summary

The purpose of the study is to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous bolus followed by prolonged infusion ("6 hr micro-dose ?"). The first part of the study will use a single-escalating dose design aimed at identifying the maximum sub-psychedelic dose, ("in humans?") while the second part will test the effects of repeated administrations ("6 hr micro-dose") of this dose ("in humans""!").